# A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

> **NCT05710848** · PHASE1,PHASE2 · RECRUITING · sponsor: **SURGE Therapeutics** · enrollment: 75 (estimated)

## Conditions studied

- Non-muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** STM-416

## Key facts

- **NCT ID:** NCT05710848
- **Lead sponsor:** SURGE Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-05
- **Final completion:** 2026-08
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710848, "A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05710848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*